Rapid review and case studies from Member States
Psychoactive substance use affects the functioning of the brain and leads to impaired driving
Depression is a leading cause of non-fatal disease burden worldwide, with a lifetime prevalence of 9% among European adult men and 17% among European adult women.
The task at hand requires substantial investments in preventive mental health care, but the potential benefits can be equally rewarding.... After all, mental wellbeing is a key resource for learning, productivity, participation and inclusion. Investing in proactive care to promote, protect and sustain mental health in the population is therefore likely to offer good value for money.
more
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more
Mood disorders
Chapter E.4
2018 edition
Anxiety disorders
Chapter F.3
Other disorders Chapter H.1
Psychiatry and Pediatrics
Chapter I.4
Attention-Deficit/Hyperactivity Disorder
Externalizing disorders
Chapter D.1
Attention deficit hyperactivity disorder
This publication is intended for professionals training or practicing in mental health and not for the general public. The opinions
expressed are those of the authors and do not necessarily represent the views of the Editor or IACAPAP. This publication seeks to
describe the best treatments and pra...ctices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws of their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all dosages and unwanted effects are mentioned. Organizations, publications and websites are cited or linked to illustrate issues or as a source of further information. This does not mean that authors, the Editor or IACAPAP endorse their content or recommendations, which should be critically assessed by the reader. Websites may also change or cease to exist.
more
Trastornos de ansiedad
Capítulo F.3
Editores: Laura Revert, Matías Irarrázaval & Andres Martin
Traducción: Régis Villegas, Paula Placencia, José Ángel Alda & Paula Cox
Troubles Anxieux
Chapitre F.3
Edition en français
Traduction : Alexis Revet
Sous la direction de : Jean-Philippe Raynaud Avec le soutien de la SFPEADA
Autres troubles
Chapitre H.3
Edition en français Traduction : Sevan Minassian Sous la direction de : Priscille Gérardin Avec le soutien de la SFPEADA